These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 28441264)

  • 1. CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.
    Fischer J; Paret C; El Malki K; Alt F; Wingerter A; Neu MA; Kron B; Russo A; Lehmann N; Roth L; Fehr EM; Attig S; Hohberger A; Kindler T; Faber J
    J Immunother; 2017 Jun; 40(5):187-195. PubMed ID: 28441264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
    Sotillo E; Barrett DM; Black KL; Bagashev A; Oldridge D; Wu G; Sussman R; Lanauze C; Ruella M; Gazzara MR; Martinez NM; Harrington CT; Chung EY; Perazzelli J; Hofmann TJ; Maude SL; Raman P; Barrera A; Gill S; Lacey SF; Melenhorst JJ; Allman D; Jacoby E; Fry T; Mackall C; Barash Y; Lynch KW; Maris JM; Grupp SA; Thomas-Tikhonenko A
    Cancer Discov; 2015 Dec; 5(12):1282-95. PubMed ID: 26516065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
    Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
    Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
    Qiu S; Pan Y; Shi S; Omotoyosi FF; Chen K; Guo Z; Lü P
    Cancer Biother Radiopharm; 2022 Jun; 37(5):335-341. PubMed ID: 33739864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
    Ruella M; Barrett DM; Kenderian SS; Shestova O; Hofmann TJ; Perazzelli J; Klichinsky M; Aikawa V; Nazimuddin F; Kozlowski M; Scholler J; Lacey SF; Melenhorst JJ; Morrissette JJ; Christian DA; Hunter CA; Kalos M; Porter DL; June CH; Grupp SA; Gill S
    J Clin Invest; 2016 Oct; 126(10):3814-3826. PubMed ID: 27571406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
    Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
    Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
    J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
    Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
    Li X; Chen W
    Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
    Aldoss I; Forman SJ
    Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.